BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22706252)

  • 1. Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation.
    Alejandre ME; Pavlovsky MA; Remaggi G; Corrado C; Fernandez I; Milone G; Pavlovsky A; Madalena L; Pandolfo M; Facio ML; Bresciani P; Pavlovsky S; Pizzolato MA
    Clin Chem Lab Med; 2012 Apr; 50(6):1093-7. PubMed ID: 22706252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience.
    Alejandre ME; Madalena LB; Pavlovsky MA; Facio ML; Corrado C; Milone G; Bresciani PD; Fraind SA; Pavlovsky S; Pizzolato MA
    Clin Chem Lab Med; 2010 May; 48(5):727-31. PubMed ID: 20450334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition.
    de Larrea CF; Cibeira MT; Elena M; Arostegui JI; Rosiñol L; Rovira M; Filella X; Yagüe J; Bladé J
    Blood; 2009 Dec; 114(24):4954-6. PubMed ID: 19797521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Clinical Significance of Oligoclonal Bands in Patient with Multiple Myeloma].
    Liu JH; Fan HS; Yan WQ; Xu JY; Li LN; Xu Y; Yi SH; Zou DH; Qiu LG; An G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1453-1463. PubMed ID: 36208249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of SPE, IFE, and FLC in Monitoring Patients with Multiple Myeloma After Autologous Stem Cell Transplantation.
    Li W; Zhou JZ; Chang HR; Dai LJ; Zhu ZL; Feng YF; Gong FR; Wu DP
    Cell Biochem Biophys; 2015 Dec; 73(3):643-7. PubMed ID: 27259306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Franke N; Winter A; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2014 Oct; 55(10):2284-9. PubMed ID: 24354684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
    Tovar N; Fernández de Larrea C; Pedrosa F; Aróstegui JI; Cibeira MT; Rosiñol L; Elena M; Filella X; Yagüe J; Bladé J
    Ann Hematol; 2014 Jan; 93(1):107-11. PubMed ID: 24218189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
    Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.
    Tovar N; de Larrea CF; Aróstegui JI; Cibeira MT; Rosiñol L; Rovira M; Elena M; Filella X; Yagüe J; Bladé J
    Haematologica; 2013 Jul; 98(7):1142-6. PubMed ID: 23645688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
    Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
    PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligoclonal reconstitution masquerading as myeloma relapse.
    Chim CS; Chan EY
    Ann Hematol; 2013 Jun; 92(6):847-8. PubMed ID: 23150202
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies.
    Harding SJ; Mead GP; Bradwell AR; Berard AM
    Clin Chem Lab Med; 2009; 47(3):302-4. PubMed ID: 19676141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.
    Fujisawa M; Seike K; Fukumoto K; Suehara Y; Fukaya M; Sugihara H; Takeuchi M; Matsue K
    Cancer Sci; 2014 Nov; 105(11):1442-6. PubMed ID: 25182124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
    Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
    Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of serum free light chain in patients with multiple myeloma].
    Zhang SS; Wu S; Qu XY; Xu J; Liu P; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):930-5. PubMed ID: 23998588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.